Views & Analysis Will plausibility reign supreme in Lyrica second medical use... Pharma needs clarity from the Supreme Court on whether the whole scope of a patent claim must be plausible at the time of the application.
Events Partner Content 2018 Off-Label Regulatory Compliance Congress Explore the Ever-Changing Regulatory Landscape
Events Partner Content Responding to the Opioid Crisis: Litigation, Regulation &... There are numerous pharmaceutical and plaintiff conferences on the opioid crisis, but none that cover the legal and regulatory aspects from BOTH sides of litigation.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
